Conditions: Healthy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 6
Healthy volunteers: yes

Brief summary:
The purpose of this study is to measure how much LY3337641 gets into the bloodstream and how long it takes the body to get rid of it. In addition, the safety and tolerability of the study drug will be evaluated.

Participants will be admitted to a clinical research unit (CRU) the day before dosing. Participants remain confined to the CRU for at least 7 days. Participants may be discharged from the CRU any time after 7 days post-dose (Day 8), and up to a maximum of 21 days post-dose (Day 22).

This study will last approximately 30 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.

Detailed description:

Arms:
arm 1: Participants received 20 milligrams (mg) oral dose of LY3337641 containing 120 microcuries of radioactivity.

Interventions: intervention 1: [¹⁴C]-LY3337641
Intervention descriptions: intervention 1: Administered orally

Protocol document: